UNSPSC 51286705: Ormetoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C14H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M3EFS94984, chemically known as 2,4-pyrimidinediamine, 5-((4,5-dimethoxy-2-methylphenyl)methyl)- but more generally known as ormetoprim, which bears US NIH Compound Identifier 23418. European Medicines Agency schedules Ormetoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09463MIG.

The term ORMETOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, No. 10 1969, List 9). ORMETOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC(CC2C(NC(NC2)N)N)C(CC1OC)C)C.

UNSPSC 51286705 Ormetoprim is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not reflect direct purchasing of ormetoprim itself. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities tagged to this code that actually solicit antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), naloxone, and drug deactivation systems—products outside the ormetoprim scope. State and local governments use this code segment to procure pharmaceuticals and medical supplies through cooperative purchasing vehicles and competitive bidding, often bundling multiple drug products or health-support items into single awards. The issuing bodies include state health departments and county health systems seeking to stock emergency medications and harm-reduction supplies for public health programs and community health initiatives.

The Illinois Department of Public Health awarded a piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392) for antibiotic pharmaceuticals totaling $2.99 million over three years via an Invitation for Bid process. Seminole County, Florida released a competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, funded potentially through FEMA with requirements for federal compliance and E-Verify verification. Recent activity centers in Florida and Illinois; the code shows limited direct purchasing volume for ormetoprim as named, and business development professionals should verify whether opportunities tagged to this code match their actual product or service line before pursuing.